share_log

啓明醫療-B：(1) 復牌進展季度更新；及 (2) 繼續暫停買賣

VENUS MEDTECH-B: (1) QUARTERLY UPDATE ON RESUMPTION PROGRESS; AND (2) CONTINUED SUSPENSION OF TRADING

香港交易所 ·  Feb 25 05:06
Summary by Moomoo AI
啟明醫療-B（股份代號：2500）於2024年2月23日發布公告，更新了自2023年11月23日起股份暫停買賣後的復牌進展情況。公告提到，公司業務營運正常，並未受未經授權交易事件重大影響，但正在評估財務影響。公司已按聯交所要求進行法證調查，並已實施特別委員會建議的行動。此外，公司進行了內部控制系統檢討，並委任新的首席財務官。公司正尋找合適人選填補獨立非執行董事及董事委員會空缺，以符合上市規則。股份將繼續暫停買賣，直至滿足復牌指引。
啟明醫療-B（股份代號：2500）於2024年2月23日發布公告，更新了自2023年11月23日起股份暫停買賣後的復牌進展情況。公告提到，公司業務營運正常，並未受未經授權交易事件重大影響，但正在評估財務影響。公司已按聯交所要求進行法證調查，並已實施特別委員會建議的行動。此外，公司進行了內部控制系統檢討，並委任新的首席財務官。公司正尋找合適人選填補獨立非執行董事及董事委員會空缺，以符合上市規則。股份將繼續暫停買賣，直至滿足復牌指引。
Kai Ming Medical -B (stock code: 2500) issued a notice on February 23, 2024, updating the progress of the re-licensing after the suspension of trading of shares since November 23, 2023. The announcement noted that the company's business is operating normally and has not been significantly affected by the unauthorized transaction incident, but the financial impact is being assessed. The Company has conducted a forensic investigation as requested by the Exchange and has taken the action recommended by the Special Committee. In addition, the company conducted an internal control system review and appointed a new chief financial officer. The Company is seeking the right person to fill vacancies for Independent Non-Executive Directors and Board Committees to comply with the Listing Rules. The shares will continue to suspend trading until the Replication Guidance is met.
Kai Ming Medical -B (stock code: 2500) issued a notice on February 23, 2024, updating the progress of the re-licensing after the suspension of trading of shares since November 23, 2023. The announcement noted that the company's business is operating normally and has not been significantly affected by the unauthorized transaction incident, but the financial impact is being assessed. The Company has conducted a forensic investigation as requested by the Exchange and has taken the action recommended by the Special Committee. In addition, the company conducted an internal control system review and appointed a new chief financial officer. The Company is seeking the right person to fill vacancies for Independent Non-Executive Directors and Board Committees to comply with the Listing Rules. The shares will continue to suspend trading until the Replication Guidance is met.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more